BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 35603183)

  • 1. Identification of CD4
    Ning S; Wu J; Pan Y; Qiao K; Li L; Huang Q
    Front Immunol; 2022; 13():880769. PubMed ID: 35603183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a CD4+ conventional T cells-related lncRNAs signature associated with hepatocellular carcinoma prognosis, therapy, and tumor microenvironment.
    Zhu L; Zhang XP; Xu S; Hu MG; Zhao ZM; Zhao GD; Xiao ZH; Liu R
    Front Immunol; 2022; 13():1111246. PubMed ID: 36700197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
    Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel ferroptosis-related long noncoding RNA signature for relapse free survival prediction in patients with breast cancer.
    Wang Y; Xu Y; Zhang Y
    Medicine (Baltimore); 2022 Aug; 101(31):e29573. PubMed ID: 35945765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer.
    Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X
    Front Immunol; 2023; 14():1145552. PubMed ID: 36969219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
    Liu Y; He X; Yang YI
    J Biosci; 2024; 49():. PubMed ID: 38287674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer.
    Qiu P; Guo Q; Lin J; Pan K; Chen J; Ding M
    Sci Rep; 2022 Dec; 12(1):22322. PubMed ID: 36566321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Analysis of RNA Binding Protein-Related lncRNA Prognostic Signature for Breast Cancer Patients.
    Xu S; Xie J; Zhou Y; Liu H; Wang Y; Li Z
    Genes (Basel); 2022 Feb; 13(2):. PubMed ID: 35205391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and validation of a transient receptor potential-related long noncoding RNA signature for prognosis prediction in breast cancer patients.
    Guo Q; Qiu P; Pan K; Chen J; Wang B; Lin J
    Medicine (Baltimore); 2023 Nov; 102(46):e35978. PubMed ID: 37986367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.
    Ma W; Zhao F; Yu X; Guan S; Suo H; Tao Z; Qiu Y; Wu Y; Cao Y; Jin F
    J Transl Med; 2020 Nov; 18(1):442. PubMed ID: 33225954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer.
    Chen F; Yang J; Fang M; Wu Y; Su D; Sheng Y
    J Clin Lab Anal; 2022 Apr; 36(4):e24302. PubMed ID: 35229919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Five Immune-Related lncRNAs Predicting Survival and Tumor Microenvironment Characteristics in Breast Cancer.
    Xiao R; Yang M; Tan Y; Ding R; Li D
    Comput Math Methods Med; 2021; 2021():6676692. PubMed ID: 33727952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Autophagy-related Long Non-coding RNA Signature for Breast Cancer.
    Jiang F; Wu C; Wang M; Wei K; Wang J
    Comb Chem High Throughput Screen; 2022; 25(8):1327-1335. PubMed ID: 34082670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
    Wang Z; Liu H; Gong Y; Cheng Y
    Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-Talk Between m
    Song W; Ren J; Xiang R; Yuan W; Fu T
    Front Immunol; 2022; 13():740960. PubMed ID: 35350786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.